{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T04:53:36Z","timestamp":1782708816777,"version":"3.54.5"},"reference-count":18,"publisher":"CSIRO Publishing","issue":"2","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1071\/journalslicense"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Long-acting injectable cabotegravir\/rilpivirine provides an alternative to daily oral antiretroviral therapy for people living with HIV, but is limited by its clinic-based delivery model. The aim of this study was to describe the implementation and early outcomes of a Hospital in the Home (HITH) program delivering long-acting injectable antiretroviral therapy within an Australian tertiary health service.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A structured protocol for HITH-based delivery of cabotegravir\/rilpivirine was developed at a single tertiary centre in Melbourne, Australia. The program was established through collaboration between infectious diseases clinicians, HITH physicians, nursing leadership and pharmacy. Processes were designed for patient selection, induction dosing, medication storage, cold-chain transport, clinical documentation and escalation of care. HITH staff received targeted training in HIV care, injection technique and stigma-sensitive communication. Following the first dose in clinic, subsequent injections were administered at home every 8\u00a0weeks, with pre-visit telephone assessments, post-dose telehealth reviews and routine pathology monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The program was integrated into existing HITH infrastructure without additional resources. One patient has completed five treatment doses, all delivered safely within dosing timeframes. Laboratory monitoring confirmed continued viral suppression. Nursing staff reported high satisfaction, describing the model as patient-centred and professionally rewarding. Operationally, coordination between HITH pharmacy, nursing and infectious diseases teams was efficient and sustainable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>HITH delivery of cabotegravir\/rilpivirine is feasible, safe and well accepted, providing a scalable, decentralised model for HIV treatment in Australia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1071\/sh25237","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T07:26:29Z","timestamp":1769671589000},"source":"Crossref","is-referenced-by-count":1,"title":["Implementation of a Hospital in the Home model for delivery of long-acting injectable antiretroviral therapy to people living with HIV: development, integration and early experience"],"prefix":"10.1071","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1722-6925","authenticated-orcid":true,"given":"Connie","family":"Lam","sequence":"first","affiliation":[{"name":"ADepartment of Infectious Diseases and Immunology, Austin Health, Melbourne Vic, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5466-1099","authenticated-orcid":true,"given":"Madeleine","family":"Bangham","sequence":"additional","affiliation":[{"name":"ADepartment of Infectious Diseases and Immunology, Austin Health, Melbourne Vic, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Rose","sequence":"additional","affiliation":[{"name":"ADepartment of Infectious Diseases and Immunology, Austin Health, Melbourne Vic, Australia."},{"name":"BDepartment of Infectious Diseases, University of Melbourne at the Peter Doherty Institute of Infection and Immunity, Melbourne Vic, Australia."},{"name":"CThe National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne Vic, Australia."},{"name":"DHospital in the Home & Virtual Care, Austin Health, Melbourne Vic, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6667-2868","authenticated-orcid":true,"given":"Shanti","family":"Narayanasamy","sequence":"additional","affiliation":[{"name":"ADepartment of Infectious Diseases and Immunology, Austin Health, Melbourne Vic, Australia."},{"name":"DHospital in the Home & Virtual Care, Austin Health, Melbourne Vic, Australia."},{"name":"EDuke Global Health Institute, Duke University, Durham, NC, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Sullivan","sequence":"additional","affiliation":[{"name":"DHospital in the Home & Virtual Care, Austin Health, Melbourne Vic, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Dowling","sequence":"additional","affiliation":[{"name":"DHospital in the Home & Virtual Care, Austin Health, Melbourne Vic, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8660-5558","authenticated-orcid":true,"given":"Janine","family":"Trevillyan","sequence":"additional","affiliation":[{"name":"ADepartment of Infectious Diseases and Immunology, Austin Health, Melbourne Vic, Australia."},{"name":"BDepartment of Infectious Diseases, University of Melbourne at the Peter Doherty Institute of Infection and Immunity, Melbourne Vic, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"67","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"issue":"1","key":"2026021519013571200_R1","doi-asserted-by":"publisher","DOI":"10.1080\/20008198.2021.1990527","article-title":"HIV\/AIDS stigma and psychological well-being after 40 years of HIV\/AIDS: a systematic review and meta-analysis.","volume":"12","author":"Rzeszutek","year":"2021","journal-title":"Eur J Psychotraumatol"},{"issue":"7","key":"2026021519013571200_R2","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1007\/s10461-011-9942-x","article-title":"Adherence to highly active antiretroviral therapy (HAART): a meta-analysis.","volume":"15","author":"Ortego","year":"2011","journal-title":"AIDS Behav"},{"issue":"1","key":"2026021519013571200_R3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/QAD.0b013e3282f366ff","article-title":"Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance.","volume":"22","author":"Gardner","year":"2008","journal-title":"AIDS"},{"issue":"9","key":"2026021519013571200_R4","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1097\/00002030-200106150-00015","article-title":"Non-adherence to highly active antiretroviral therapy predicts progression to AIDS.","volume":"15","author":"Bangsberg","year":"2001","journal-title":"AIDS"},{"issue":"12","key":"2026021519013571200_R5","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression.","volume":"382","author":"Swindells","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"2026021519013571200_R6","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","article-title":"Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection.","volume":"382","author":"Orkin","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"2026021519013571200_R7","doi-asserted-by":"publisher","first-page":"e185","DOI":"10.1016\/S2352-3018(20)30340-4","article-title":"Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.","volume":"8","author":"Orkin","year":"2021","journal-title":"Lancet HIV"},{"issue":"10267","key":"2026021519013571200_R8","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.","volume":"396","author":"Overton","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"2026021519013571200_R9","doi-asserted-by":"publisher","first-page":"e679","DOI":"10.1016\/S2352-3018(21)00185-5","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.","volume":"8","author":"Jaeger","year":"2021","journal-title":"Lancet HIV"},{"issue":"8","key":"2026021519013571200_R10","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1111\/hiv.13647","article-title":"Real-world use of long-acting cabotegravir and rilpivirine: 12-month results of the inJectable Antiretroviral therapy feasiBility Study (JABS).","volume":"25","author":"John","year":"2024","journal-title":"HIV Med"},{"issue":"3","key":"2026021519013571200_R11","doi-asserted-by":"publisher","first-page":"e645","DOI":"10.1093\/cid\/ciac631","article-title":"First demonstration project of long-acting injectable antiretroviral therapy for persons with and without detectable human immunodeficiency virus (HIV) viremia in an urban HIV clinic.","volume":"76","author":"Christopoulos","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2026021519013571200_R12","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1089\/apc.2024.0067","article-title":"Perspectives among health care providers and people with HIV on the implementation of long-acting injectable cabotegravir\/rilpivirine for antiretroviral therapy in Florida.","volume":"38","author":"Fisk-Hoffman","year":"2024","journal-title":"AIDS Patient Care STDS"},{"issue":"4","key":"2026021519013571200_R13","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1097\/QAD.0000000000003476","article-title":"Long-acting cabotegravir\/rilpivirine for HIV-1 treatment: real-world evaluation of barriers to implementation.","volume":"37","author":"Wood","year":"2023","journal-title":"AIDS"},{"issue":"9","key":"2026021519013571200_R14","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26003","article-title":"Perspectives of healthcare providers on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III implementation-effectiveness study (CUSTOMIZE).","volume":"25","author":"Czarnogorski","year":"2022","journal-title":"J Int AIDS Soc"},{"issue":"9","key":"2026021519013571200_R15","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1089\/apc.2023.0154","article-title":"Receipt of injectable HIV treatment in clinic versus at home: perspectives of persons living with HIV infection.","volume":"37","author":"Adekunle","year":"2023","journal-title":"AIDS Patient Care STDS"},{"issue":"3","key":"2026021519013571200_R16","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1093\/cid\/ciae472","article-title":"Comparison of at-home versus in-clinic receipt of long-acting injectable cabotegravir\/rilpivirine.","volume":"80","author":"Kirk","year":"2025","journal-title":"Clin Infect Dis"},{"issue":"9","key":"2026021519013571200_R17","doi-asserted-by":"publisher","first-page":"512","DOI":"10.5694\/mja12.10480","article-title":"A meta-analysis of \u201chospital in the home\u201d.","volume":"197","author":"Caplan","year":"2012","journal-title":"Med J Aust"},{"issue":"4","key":"2026021519013571200_R18","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/s11904-019-00454-5","article-title":"A review of differentiated service delivery for HIV treatment: effectiveness, mechanisms, targeting, and scale.","volume":"16","author":"Roy","year":"2019","journal-title":"Curr HIV AIDS Rep"}],"container-title":["Sexual Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/connectsci.au\/sh\/article-pdf\/doi\/10.1071\/SH25237\/1856454\/sh25237.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/connectsci.au\/sh\/article-pdf\/doi\/10.1071\/SH25237\/1856454\/sh25237.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:01:41Z","timestamp":1771200101000},"score":1,"resource":{"primary":{"URL":"https:\/\/connectsci.au\/sh\/article\/23\/2\/SH25237\/268744\/Implementation-of-a-Hospital-in-the-Home-model-for"}},"subtitle":[],"editor":[{"given":"Darren","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4,9]]}},"URL":"https:\/\/doi.org\/10.1071\/sh25237","relation":{},"ISSN":["1448-5028","1449-8987"],"issn-type":[{"value":"1448-5028","type":"print"},{"value":"1449-8987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"article-number":"SH25237"}}